Discovery of a Potent Dual ALK and EGFR T790M Inhibitor

The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Med Chem
Autori principali: Jang, Jaebong, Son, Jung Beom, To, Ciric, Bahcall, Magda, Kim, So Young, Kang, Seock Yong, Mushajiang, Mierzhati, Lee, Younho, Jänne, Pasi A., Choi, Hwan Geun, Gray, Nathanael S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800871/
https://ncbi.nlm.nih.gov/pubmed/28528303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2017.04.079
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi